Exact Sciences Corp EXAS:NASDAQ

Last Price$85.17NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/11/19

Today's Change-0.13(0.15%)
Bid (Size)$83.50 (1)
Ask (Size)$86.01 (2)
Day Low / High$83.99 - 85.76
Volume1.1 M

View Biotechnology IndustryPeer Comparison as of 12/11/2019


Exact Sciences Corp ( NASDAQ )

Price: $85.17
Change: -0.13 (0.15%)
Volume: 1.1 M
4:00PM ET 12/11/2019

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $118.79
Change: -3.05 (2.50%)
Volume: 522.8 K
3:59PM ET 12/11/2019

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $78.77
Change: -0.66 (0.83%)
Volume: 1.0 M
4:00PM ET 12/11/2019

Neurocrine Biosciences Inc ( NASDAQ )

Price: $113.25
Change: -0.40 (0.35%)
Volume: 1.7 M
3:59PM ET 12/11/2019

Ionis Pharmaceuticals Inc ( NASDAQ )

Price: $61.69
Change: -1.22 (1.94%)
Volume: 786.4 K
4:00PM ET 12/11/2019

Read more news Recent News

Insider Makes Significant Stock Sells in Exact Sciences (EXAS) Shares
10:18PM ET 11/26/2019 MT Newswires

There was a notable sale of shares of Exact Sciences by an insider today, as disclosed in a form 4 document filed with the SEC. One insider -- G Bradley...

Insider Trends: Insider Sales Continue 90-Day Trend at Exact Sciences
5:20PM ET 11/25/2019 MT Newswires

G Bradley Cole, General Manager - Diagnostics, executed a sale of 28,016 shares of Exact Sciences (EXAS) on Nov 21, 2019, for $2,251,926. After the Form 4...

Analyst Actions: Stifel Nicolaus Initiates Coverage on Exact Sciences With Buy Rating, $110 Price Target
8:36AM ET 11/15/2019 MT Newswires

Exact Sciences' (EXAS) average rating among analysts is a buy, with an average price target of $126. Price: 80.87, Change: +1.63, Percent Change: +2.06 ...

Exact Sciences Completes Acquisition of Genomic Health
12:07PM ET 11/08/2019 MT Newswires

Exact Sciences (EXAS), a provider of cancer screening and diagnostic tests, has completed the acquisition of Genomic Health (GHDX), according to a release...

Company Profile

Business DescriptionEXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI. View company web site for more details
Address441 Charmany Drive
Madison, Wisconsin 53719
Number of Employees1,977
Recent SEC Filing11/27/20198-K
Chairman, President & Chief Executive OfficerKevin T. Conroy
Senior Vice President-OperationsAna Hooker
Chief Financial OfficerJeffrey T. Elliott
Co-Chief Medical Officer & Head-Medical AffairsBarry M. Berger

Company Highlights

Price Open$85.30
Previous Close$85.30
52 Week Range$53.06 - 123.99
Market Capitalization$11.1 B
Shares Outstanding129.8 M
SectorHealth Technology
Next Earnings Announcement02/20/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.71
Beta vs. S&P 500N/A
Revenue$454.5 M
Net Profit Margin-29.83%
Return on Equity-29.06%

Analyst Ratings as of 11/22/2019

Consensus RecommendationConsensus Icon
Powered by Factset